Related Experiment Video
Updated: May 31, 2026
09:47
Isolation of CD146+ Resident Lung Mesenchymal Stromal Cells from Rat Lungs
Published on: June 17, 2016
Mesenchymal stem cells and acute lung injury
Jeffrey E Gotts1, Michael A Matthay
1Department of Medicine Anesthesiology, The Cardiovascular Research Institute, University of California, 505 Parnassus Avenue, Moffitt Hospital, Room M-917, San Francisco, CA 94143-0624, USA. jeffrey.gotts@ucsf.edu
Critical Care Clinics
|July 12, 2011
Summary
Mesenchymal stem cells (MSCs) show promise for treating acute respiratory distress syndrome (ARDS), a severe lung condition. This review explores MSC properties and their potential in preclinical ARDS models.
Area of Science:
- Pulmonology
- Regenerative Medicine
- Cell Biology
Background:
- Acute respiratory distress syndrome (ARDS) is a critical condition characterized by acute respiratory failure, hypoxemia, and bilateral pulmonary infiltrates.
- Its pathogenesis involves lung endothelial and alveolar epithelial injury, leading to fluid and debris accumulation in alveoli.
- Currently, no pharmacologic therapies are proven effective for ARDS.
Purpose of the Study:
- To review the fundamental properties of mesenchymal stem cells (MSCs).
- To examine the application of MSCs in preclinical models of lung injury and ARDS.
- To explore potential therapeutic mechanisms of MSCs in ARDS.
Main Methods:
- Review of existing literature on mesenchymal stem cells.
- Analysis of preclinical studies investigating MSCs in lung injury and ARDS models.
- Synthesis of data on MSC properties and therapeutic potential.
Main Results:
- MSCs possess properties that make them suitable for cell-based therapies.
- Preclinical models demonstrate the potential efficacy of MSCs in mitigating lung injury and ARDS.
- Identified potential therapeutic mechanisms include immunomodulation and tissue repair.
Conclusions:
- Mesenchymal stem cells represent a promising therapeutic strategy for ARDS.
- Further research into MSC mechanisms and clinical application is warranted.
- Cell-based therapies offer a novel approach to managing ARDS.
